

NAME OF THE COMPANY: M/S. BLISS GVS PHARMA LIMITED
CIN NO.: L24230MH1984PLC034771
BSE CODE: 506197
QUARTER: 01.04.2015 TO 30.06.2015

Particulars	Clause of Listing agreement	Compliance Status Yes/No/	Remarks
II. Board of Directors	49 (II)	Y	
(A) Composition of Board	49 (IIA)	Y	
(B) Independent Directors	49 (IIB)	Y	
(C) Non-executive Directors'	49 (IIC)	Y	
(D) Other provisions as to Board and	49 (IID)	Y	
(E) Code of Conduct	49 (IIE)	Y	
(F) Whistle Blower Policy	49 (IIF)	Y	
III. Audit Committee	49 (III)	Y	
(A) Qualified & Independent Audit	49 (IIIA)	Y	
(B) Meeting of Audit Committee	49 (IIIB)	Y	
(C) Powers of Audit Committee	49 (IIIC)	Y	
(D) Role of Audit Committee	49 (IIID)	Y	
(E) Review of Information by Audit	49 (IIIE)	Y	
IV. Nomination and Remuneration	49 (IV)	Y	
V. Subsidiary Companies	49 (V)	Y	
VI. Risk Management	49 (VI)	Y	
VII. Related Party Transactions	49 (VII)	Y	
VIII. Disclosures	49 (VIII)	Y	
(A) Related party transactions	49 (VIIIA)	Y	There are related party transactions In this quarter.
(B) Disclosure of Accounting Treatment	49 (VIIIB)	Y	On a going concern basis and as per accounting standards.
(C) Remuneration of Directors	49 (VIII C)	Y	Details are part of proper disclosure in the Annual Report. The non- executive Directors are only receiving sittings fees.
(D) Management	49 (VIII D)	Y	Shall be disclosed in the Annual report. Earlier disclosures were disclosed in the last Annual report.



(E) Shareholders	49 (VIII E)	Y	There were no new appointment for this quarter.
(F) Proceeds from public issues,	49 (VIII F)	NA	NA
IX. CEO/CFO Certification	49 (IX)	Y	Shall be disclosed in the Annual report. Earlier disclosures were disclosed in the last Annual report.
X. Report on Corporate Governance	49 (X)	Y	Shall be disclosed in the Annual report. Earlier disclosures were disclosed in the last Annual report.
XI. Compliance	49 (XI)	Y	Shall be disclosed in the Annual report. Earlier disclosures were disclosed in the last Annual report.

** Mr. G.G. Desai – Chairman cum Independent Director resigned from the Board on 29/05/2015 . The Board is taking adequate steps to reconstitute the committee in this quarter starting from 1st July, 2015.

FOR BLISS GVS PHARMA LIMITED

VIPUL THAKKAR
GM-CORPORATE FINANCE

